Rapport Therapeutics initiated with a Strong Buy at Raymond James

Raymond James analyst Tiago Fauth last night initiated coverage of Rapport Therapeutics (RAPP) with a Strong Buy rating and $66 price target The firm believes investors are not paying attention to RAP-219’s Phase 2 readout in bipolar mania in the first half of 2027. This will change soon, the analyst tells investors in a research note. Raymond James suspects 95% of the Street’s focus and Rapport’s current valuation is on RAP-219’s program in focal onset seizures. The Phase 2 readout in bipolar mania is the key catalyst that could double Rapport’s peak sales opportunity, the firm contends.